ABSTRACT: Endocannabinoids and some phytocannabinoids bind to CB1 and CB2cannabinoid receptors, transient receptor potential vanilloid one (TRPV1) receptor and the orphan G protein receptor fifty-five (GPR55). Studies using C57BL/10 and C57BL/6 (Cnr2tm1Zim) CB2 cannabinoid receptor knockout mice have demonstrated an immune-augmenting effect in experimental autoimmune ... Continue Reading
GPR55
STUDY: A role for L-α-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells
ABSTRACT: Background and purpose: Increased circulating levels of L-α-lysophosphatidylinositol (LPI) are associated with cancer and LPI is a potent, ligand for the G-protein-coupled receptor GPR55. Here we have assessed the modulation of breast cancer cell migration, orientation and polarization by LPI and GPR55. Experimental approach: Quantitative RT-PCR was used ... Continue Reading
STUDY: New blood brothers: the GPR55 and CB2 partnership
ABSTRACT: Endocannabinoids are increasingly being recognized as key lipid-derived regulators of immune function 1. Although the peripheral cannabinoid type 2 receptor (CB2) is thought to orchestrate many of these actions, additional non-CB1/CB2-mediated effects of cannabinoids have been identified in immune cells 1, 2, where several orphan G protein-coupled receptors ... Continue Reading
STUDY: Lysophosphatidylinositol Causes Neurite Retraction via GPR55, G13 and RhoA in PC12 Cells
ABSTRACT: GPR55 was recently identified as a putative receptor for certain cannabinoids, and lysophosphatidylinositol (LPI). Recently, the role of cannabinoids as GPR55 agonists has been disputed by a number of reports, in part, because studies investigating GPR55 often utilized overexpression systems, such as the GPR55-overexpressing HEK293 cells, which make it difficult to ... Continue Reading
STUDY: Receptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists
ABSTRACT: It is widely accepted that non-endogenous compounds that target CB1 and/or CB2receptors possess therapeutic potential for the clinical management of an ever growing number of disorders. Just a few of these disorders are already treated with Δ9-tetrahydrocannabinol or nabilone, both CB1/CB2 receptor agonists, and there is now considerable interest in expanding the ... Continue Reading